Article
Engineering, Environmental
Linping Zhao, Chuyu Huang, Rongrong Zheng, Xiaona Rao, Renjiang Kong, Runtian Guan, Zuxiao Chen, Xiyong Yu, Hong Cheng, Shiying Li
Summary: In this study, a self-delivery bioregulator called C-Moc was developed for photodynamic amplified immune checkpoint-blockade (ICB) therapy by epigenetic reprogramming. C-Moc, prepared through the self-assembly of chlorine e6 (Ce6) and mocetinostat (Moc), showed improved stability, cellular uptake, and pharmacokinetics. It preferentially accumulated at tumor sites and induced immunogenic cell death (ICD) upon light irradiation. The increased expressions of MHC-I and PD-L1 mediated by C-Moc through epigenetic reprogramming enhanced the recognition of tumor cells by the immune system and improved the ICB therapy of alpha-PD-L1. Overall, the photodynamic amplified ICB therapy of C-Moc showed great superiority in suppressing primary and distant tumors.
CHEMICAL ENGINEERING JOURNAL
(2023)
Article
Oncology
Shengchen Su, Sungyong You, Yanping Wang, Patrick Tamukong, Michael J. Quist, Catherine S. Grasso, Hyung L. Kim
Summary: Antitumor immunity requires lymphocytes to localize to the tumor. Prostate cancers (PCs) are immunologically cold and tend to lack T-cell infiltration. Most advanced PCs are insensitive to PD1 blockade therapies.
Review
Biochemistry & Molecular Biology
Longzheng Xia, Linda Oyang, Jinguan Lin, Shiming Tan, Yaqian Han, Nayiyuan Wu, Pin Yi, Lu Tang, Qing Pan, Shan Rao, Jiaxin Liang, Yanyan Tang, Min Su, Xia Luo, Yiqing Yang, Yingrui Shi, Hui Wang, Yujuan Zhou, Qianjin Liao
Summary: The overlapping metabolic reprogramming between cancer and immune cells is an important factor affecting the antitumor immune response, involving metabolic competition, nutrient limitation, and impaired immune cell function. Studies have shown that metabolic reprogramming is essential for maintaining immune cell homeostasis and executing effector functions during immune responses.
Article
Pharmacology & Pharmacy
Ye Li, Yuncang Yuan, Fan Zhang, Aizhen Guo, Fuao Cao, Mengmeng Song, Yating Fu, Xiaowen Xu, Hao Shen, Shangyong Zheng, Yamin Pan, Wenjun Chang
Summary: Our study found that frequent resistance to SHP2 inhibitors exists in colorectal carcinoma cells, even in those without RAS mutations. Rapid adaptive reactivation of the AKT pathway in response to SHP2 inhibition may contribute to this resistance, driven by the reactivation of RTKs or released p-FAK. Co-inhibition of FAK abrogated the feedback reactivation of AKT in response to SHP2 inhibition, leading to sustained AKT pathway suppression and improved antitumor efficacy.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Chemistry, Multidisciplinary
Elham Masoumi, Sahar Tahaghoghi-Hajghorbani, Leila Jafarzadeh, Mohammad-Javad Sanaei, Atieh Pourbagheri-Sigaroodi, Davood Bashash
Summary: This review provides an overview of the current research status of immune checkpoint blockades in breast cancer and discusses the efficacy and limitations of ICB therapy in breast cancer treatment.
JOURNAL OF CONTROLLED RELEASE
(2021)
Article
Multidisciplinary Sciences
Rosalynd Upton, Allison Banuelos, Dongdong Feng, Tanuka Biswas, Kevin Kao, Kelly McKenna, Stephen Willingham, Po Yi Ho, Benyamin Rosental, Michal Caspi Tal, Tal Raveh, Jens-Peter Volkmer, Mark D. Pegram, Irving L. Weissman
Summary: Trastuzumab, a targeted anti-HER2 monoclonal antibody, is effective for early-stage HER2(+) breast cancer but resistance often develops in advanced-stage patients. Combining trastuzumab with anti-CD47 immunotherapy shows promising results in inhibiting the growth of ADCC-tolerant HER2(+) breast cancers.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Chemistry, Multidisciplinary
Xiaowei Liu, Yanlin Feng, Jie Xu, Ying Shi, Jiqiao Yang, Rongjie Zhang, Jinen Song, Xin Bai, Xi Wu, Yu Bao, Ya Luo, Huifang Li, Li Chai, Changyang Gong, Yan Wang, Bo Chen, Jianping Hu, Yan Fu, Yongzhang Luo, Haiyuan Zhang, Hubing Shi
Summary: The research demonstrates the advantage of photothermal-targeted-immune triple combinatorial regimen in treating tumors that are clinically unresectable multifocal and lack T-cell infiltration.
JOURNAL OF CONTROLLED RELEASE
(2021)
Article
Clinical Neurology
Mark A. Petersen, Reshmi Tognatta, Anke Meyer-Franke, Eric A. Bushong, Andrew S. Mendiola, Zhaoqi Yan, Abinaya Muthusamy, Mario Merlini, Rosa Meza-Acevedo, Belinda Cabriga, Yungui Zhou, Reuben Thomas, Jae Kyu Ryu, Hans Lassmann, Mark H. Ellisman, Katerina Akassoglou
Summary: In neuroinflammatory lesions, extrinsic inhibitors such as fibrinogen lead to clustering of oligodendrocyte precursor cells and hinder remyelination, but blocking the bone morphogenetic protein signaling pathway can restore the promyelinating niche and have therapeutic effects.
Article
Oncology
Lijun Xu, Bingyu Li, Chenyu Pi, Zhaohua Zhu, Fei Tao, Kun Xie, Yan Feng, Xiaoqing Xu, Yanxin Yin, Hua Gu, Jianmin Fang
Summary: BsAbs targeting CD89 and tumor antigens can improve antigen presentation and T-cell infiltration, control tumor growth, and overcome resistance to immune checkpoint inhibitors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Chemistry, Multidisciplinary
Guiyuan Chen, Xiangxia Li, Rui Li, Kecheng Wu, Zhouhang Lei, Ruike Dai, Kyle Roche, Andrew Z. Wang, Yuanzeng Min
Summary: Researchers hypothesized that treating cancer cells with ultrahigh doses of chemotherapeutics in vitro could artificially enhance the immunogenicity, thereby improving chemoimmunotherapy.
Article
Biochemistry & Molecular Biology
Courtney T. Stump, Kevin Roehle, Nataly Manjarrez Orduno, Stephanie K. Dougan
Summary: This study shows that combination checkpoint blockade immunotherapy and radiation therapy can have a modest inhibitory effect on tumor growth in pancreatic cancer models, with significant increases in CD8+ T cells, CD4+ T cells, and tumor-specific T cells.
Article
Chemistry, Multidisciplinary
Adam A. Walters, Gemma Santacana-Font, Jin Li, Nadia Routabi, Yue Qin, Nathalie Claes, Sara Bals, Julie Tzu-Wen Wang, Khuloud T. Al-Jamal
Summary: The study demonstrates that a combination of siRNA and mRNA in a single formulation can simultaneously reduce and induce expression of immune checkpoint targets to reprogram the tumor microenvironment. Using SNALPs, efficient transfection of cells with minimal toxicity was achieved in vitro.
Review
Immunology
Mohammad Hossein Kazemi, Alireza Najafi, Jafar Karami, Foad Ghazizadeh, Hassan Yousefi, Reza Falak, Elahe Safari
Summary: Recent advancements in cancer immunotherapy, particularly immune checkpoint (IC) blockers, have shown promising results in clinical settings. Immunometabolism plays a crucial role in regulating immune responses, and dual targeting of ICs and metabolic pathways may help restore immune cells' antitumor activity.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Review
Pharmacology & Pharmacy
Pavlos Msaouel, Giannicola Genovese, Jianjun Gao, Suvajit Sen, Nizar M. Tannir
Summary: Immune checkpoint inhibitors have shown promise in cancer treatment but are not always long-lasting and effective for all patients. Targeting TAM kinases with tyrosine kinase inhibitors may enhance the efficacy of immune checkpoint blockade, but whether selective targeting of each TAM receptor or multi-receptor TAM inhibitors are more effective remains to be determined. Triple inhibition of all TAM receptors may lead to increased risk of adverse events, and clinical trial designs should focus on determining the synergistic effects of combining TAM inhibition with immune checkpoint blockade through high-resolution clinical endpoints and proper control arms.
EXPERT OPINION ON THERAPEUTIC TARGETS
(2021)
Article
Immunology
Qi-jie Zhang, Jiao-chen Luan, Le-bin Song, Rong Cong, Cheng-jian Ji, Xiang Zhou, Jia-dong Xia, Ning-hong Song
Summary: The study found no difference in efficacy between elderly and young patients in most cancer types, except for melanoma patients receiving anti-PD-1 therapy. Elderly patients showed higher treatment response rate and more favorable prognosis in certain cancer types, potentially attributed to their high mutational properties. This suggests that modulating immune function could be beneficial to immunotherapy in elderly patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Sandra Garcia-Aroz, Min Xu, Ola Ahmed, Joshua Hollingshead, Xuanchuan Wang, Babak Banan, Adeel Khan, Liang- Kang, Zhengyan Zhang, Gundumi Upadhya, Pamela Manning, Yiing Lin, William C. Chapman
Summary: The study investigates the use of antibody-mediated CD47 blockade in improving liver graft function. CD47mAb treatment reduces ischemia/reperfusion injury and enhances liver regeneration.
Article
Immunology
Tarin M. Bigley, Liping Yang, Liang- Kang, Jose B. Saenz, Francisco Victorino, Wayne M. Yokoyama
Summary: This study shows that neonatal murine roseolovirus infection disrupts central tolerance and induces autoimmune disease in adult mice. The infection is associated with the development of various autoantibodies and is dependent on the replication during neonatal period and the involvement of CD4(+) T cells and IL-17. These findings suggest that early life infection with roseolovirus can lead to disruption of central tolerance and development of autoimmune disease.
JOURNAL OF EXPERIMENTAL MEDICINE
(2022)
Article
Oncology
Andrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, Rama Suresh, Albert C. Lockhart, Amberly Brown, Marcus Breden, Jad I. Belle, John Herndon, Savannah J. Bogner, Katrina Pedersen, Benjamin Tan, Nicholas Boice, Abhi Acharya, Mina Abdiannia, Feng Gao, Harry H. Yoon, Mojun Zhu, Nikolaos A. Trikalinos, Lee Ratner, Olivia Aranha, William G. Hawkins, Brett H. Herzog, David G. Denardo
Summary: The combination therapy of defactinib, pembrolizumab, and gemcitabine showed good tolerability and safety, promising preliminary efficacy, and biomarker activity in infiltrative T lymphocytes in PDAC patients.
CLINICAL CANCER RESEARCH
(2022)
Article
Cell Biology
Brett H. Herzog, John M. Baer, Nicholas Borcherding, Natalie L. Kingston, Jad I. Belle, Brett L. Knolhoff, Graham D. Hogg, Faiz Ahmad, Liang- Kang, Jessica Petrone, Chieh-Yu Lin, Ramaswamy Govindan, David G. DeNardo
Summary: Non-small cell lung cancer (NSCLC) is a major cause of cancer-related deaths. Fibrosis in NSCLC leads to reduced immune surveillance and poor responsiveness to immune checkpoint blockade. Fibrosis-induced alterations in dendritic cells and macrophage phenotypes contribute to immunosuppression. Targeting fibrosis through transforming growth factor-II receptor signaling overcomes immunotherapeutic resistance and enhances the efficacy of immune checkpoint blockade in the context of chemotherapy.
SCIENCE TRANSLATIONAL MEDICINE
(2023)
Article
Oncology
C. Alston James, John M. Baer, Chong Zou, Usman Y. Panni, Brett L. Knolhoff, Graham D. Hogg, Natalie L. Kingston, Liang-I. Kang, Varintra E. Lander, Jingqin Luo, Yu Tao, Mark A. Watson, Rebecca Aft, Ryan C. Fields, William G. Hawkins, David G. DeNardo
Summary: Intratumoral T-cell dysfunction is a hallmark of pancreatic tumors, and the dysfunction of type 1 conventional DCs (cDC1) in PDAC is a driver of the lack of responsiveness to checkpoint immunotherapy. However, the impact of PDAC on systemic type 2 cDC2 development and function has not been well studied.
CANCER IMMUNOLOGY RESEARCH
(2023)
Article
Allergy
Daniel P. Lander, Lauren T. Roland
Summary: This review discusses the current classification schema for fungal rhinosinusitis, highlighting concerns about the criteria for allergic fungal rhinosinusitis and proposing new classifications for invasive fungal sinusitis. It also addresses the possibility that fungal sinusitis is a spectrum of disease and suggests the need for multi-institutional studies and updates to the diagnostic criteria and guidelines.
CURRENT TREATMENT OPTIONS IN ALLERGY
(2023)
Article
Immunology
John M. Baer, Chong Zuo, Liang-I Kang, Angela Alarcon de la Lastra, Nicholas C. Borcherding, Brett L. Knolhoff, Savannah J. Bogner, Yu Zhu, Liping Yang, Jennifer Laurent, Mark A. Lewis, Nan Zhang, Ki-Wook Kim, Ryan C. Fields, Wayne M. Yokoyama, Jason C. Mills, Li Ding, Gwendalyn J. Randolph, David G. DeNardo
Summary: Tissue-resident macrophages (TRMs) have distinct roles in pancreatitis and pancreatic cancer. TRMs have a protective effect during pancreatitis by activating fibroblasts, but TRM-driven fibrosis drives the pathogenesis of pancreatic cancer.